PF-4981517CYP3A4 inhibitor,potent and selective CAS# 1390637-82-7 |
- LY2606368
Catalog No.:BCC4105
CAS No.:1234015-52-1
- CHIR-124
Catalog No.:BCC3750
CAS No.:405168-58-3
- BML-277
Catalog No.:BCC4245
CAS No.:516480-79-8
- AZD7762
Catalog No.:BCC2555
CAS No.:860352-01-8
- MK-8776 (SCH-900776)
Catalog No.:BCC3817
CAS No.:891494-63-6
- SCH900776 S-isomer
Catalog No.:BCC1936
CAS No.:891494-64-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1390637-82-7 | SDF | Download SDF |
PubChem ID | 71315139 | Appearance | Powder |
Formula | C26H32N8 | M.Wt | 456.59 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 20 mM in ethanol | ||
Chemical Name | 1-methyl-3-[1-methyl-5-(4-methylphenyl)pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]pyrazolo[3,4-d]pyrimidine | ||
SMILES | CC1=CC=C(C=C1)C2=C(C=NN2C)C3=NN(C4=C3C(=NC=N4)N5CCC(C5)N6CCCCC6)C | ||
Standard InChIKey | WDWIMDKOXZZYHH-FQEVSTJZSA-N | ||
Standard InChI | InChI=1S/C26H32N8/c1-18-7-9-19(10-8-18)24-21(15-29-31(24)2)23-22-25(32(3)30-23)27-17-28-26(22)34-14-11-20(16-34)33-12-5-4-6-13-33/h7-10,15,17,20H,4-6,11-14,16H2,1-3H3/t20-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective inhibitor of CYP3A4 (IC50 values are 0.03, 17 and 70 μM for CYP3A4, CYP3A5 and CYP3A7 respectively). |
PF-4981517 Dilution Calculator
PF-4981517 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1901 mL | 10.9507 mL | 21.9015 mL | 43.803 mL | 54.7537 mL |
5 mM | 0.438 mL | 2.1901 mL | 4.3803 mL | 8.7606 mL | 10.9507 mL |
10 mM | 0.219 mL | 1.0951 mL | 2.1901 mL | 4.3803 mL | 5.4754 mL |
50 mM | 0.0438 mL | 0.219 mL | 0.438 mL | 0.8761 mL | 1.0951 mL |
100 mM | 0.0219 mL | 0.1095 mL | 0.219 mL | 0.438 mL | 0.5475 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PF-4981517, also named CYP3cide, is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. PF-4981517 is a very useful tool for understanding the relative roles of CYP3A4 versus CYP3A5 and the impact of CYP3A5 genetic polymorphism on a compound's pharmacokinetics. PF-4981517 is a lipophilic compound with a pKa which will render it cationic at physiological pH. Thus, it is possible that if incubate with high concentrations of microsomes, it can nonspecifically partition into microsomal phospholipid, and its apparent potency will be reduced. PF-4981517 should be useful to investigators seeking to delineate the relative contribution of CYP3A4 versus CYP3A5 in the metabolism of compounds cleared by CYP3A.
Reference
Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Helal, Gregory S. Walker, Theunis C. Goosen and Michael A. Zientek. Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs. DMD September 2012 vol. 40 no. 9 1686-1697.
- L-689,560
Catalog No.:BCC6774
CAS No.:139051-78-8
- Anemarsaponin B
Catalog No.:BCN6289
CAS No.:139051-27-7
- 2-PMDQ
Catalog No.:BCC6726
CAS No.:139047-55-5
- JMV 449
Catalog No.:BCC5863
CAS No.:139026-66-7
- Oplodiol
Catalog No.:BCN6204
CAS No.:13902-62-0
- Catalpin
Catalog No.:BCN6205
CAS No.:1390-72-3
- Carmine
Catalog No.:BCN2223
CAS No.:1390-65-4
- 3,4-Dihydroxybenzaldehyde
Catalog No.:BCN6214
CAS No.:139-85-5
- Ziprasidone hydrochloride monohydrate
Catalog No.:BCC2072
CAS No.:138982-67-9
- Capsazepine
Catalog No.:BCC1451
CAS No.:138977-28-3
- Coronarin D ethyl ether
Catalog No.:BCN6203
CAS No.:138965-89-6
- Isocoronarin D
Catalog No.:BCN6202
CAS No.:138965-88-5
- (-)-Heraclenol
Catalog No.:BCN7682
CAS No.:139079-42-8
- Tristin
Catalog No.:BCN4709
CAS No.:139101-67-0
- PF 4800567 hydrochloride
Catalog No.:BCC7904
CAS No.:1391052-28-0
- Vigabatrin Hydrochloride
Catalog No.:BCC5198
CAS No.:1391054-02-6
- Zanamivir
Catalog No.:BCC4946
CAS No.:139110-80-8
- BM-1074
Catalog No.:BCC2235
CAS No.:1391108-10-3
- Isomurralonginol acetate
Catalog No.:BCN4708
CAS No.:139115-59-6
- Tripterifordin
Catalog No.:BCN6206
CAS No.:139122-81-9
- Uralenol
Catalog No.:BCN7994
CAS No.:139163-15-8
- H-Tle-OH.HCl
Catalog No.:BCC2660
CAS No.:139163-43-2
- CEP-37440
Catalog No.:BCC5145
CAS No.:1391712-60-9
- ZM 241385
Catalog No.:BCC6902
CAS No.:139180-30-6
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.[Pubmed:22645092]
Drug Metab Dispos. 2012 Sep;40(9):1686-97.
CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-yl pyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme metabolic inactivation efficiency (k(inact)/K(I)) of 3300 to 3800 ml . min(-)(1) . mumol(-)(1) was observed using human liver microsomes from donors of nonfunctioning CYP3A5 (CYP3A5 *3/*3). This observed efficiency equated to an apparent K(I) between 420 and 480 nM with a maximal inactivation rate (k(inact)) equal to 1.6 min(-)(1). Similar results were achieved with testosterone, another CYP3A substrate, and other sources of the CYP3A4 enzyme. To further illustrate the abilities of CYP3cide, its partition ratio of inactivation was determined with recombinant CYP3A4. These studies produced a partition ratio approaching unity, thus underscoring the inactivation capacity of CYP3cide. When CYP3cide was tested at a concentration and preincubation time to completely inhibit CYP3A4 in a library of genotyped polymorphic CYP3A5 microsomes, the correlation of the remaining midazolam 1'-hydroxylase activity to CYP3A5 abundance was significant (R(2) value equal to 0.51, p value of <0.0001). The work presented here supports these findings by fully characterizing the inhibitory properties and exploring CYP3cide's mechanism of action. To aid the researcher, multiple commercially available sources of CYP3cide were established, and a protocol was developed to quantitatively determine CYP3A4 contribution to the metabolism of an investigational compound. Through the establishment of this protocol and the evidence provided here, we believe that CYP3cide is a very useful tool for understanding the relative roles of CYP3A4 versus CYP3A5 and the impact of CYP3A5 genetic polymorphism on a compound's pharmacokinetics.